Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the sale, the director directly owned 42,952 shares in the company, valued at approximately $2,941,352.96. The trade was a 4.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bernadette Connaughton also recently made the following trade(s):

• On Wednesday, October 1st, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00.
• On Tuesday, September 2nd, Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $71.19 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $79.50. The firm has a market capitalization of $8.37 billion, a P/E ratio of 16.29, a P/E/G ratio of 0.35 and a beta of 1.18. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company’s fifty day moving average price is $70.37 and its 200 day moving average price is $63.13.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same quarter in the prior year, the firm posted $1.27 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 22.1% on a year-over-year basis. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 0.4% during the first quarter. Envestnet Asset Management Inc. now owns 303,774 shares of the biopharmaceutical company’s stock worth $19,384,000 after purchasing an additional 1,161 shares during the period. Nisa Investment Advisors LLC raised its position in Halozyme Therapeutics by 4.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 215 shares during the last quarter. Xponance Inc. raised its position in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 198 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Halozyme Therapeutics by 0.8% in the 1st quarter. Louisiana State Employees Retirement System now owns 35,600 shares of the biopharmaceutical company’s stock worth $2,272,000 after acquiring an additional 300 shares during the period. Finally, CWM LLC boosted its holdings in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, October 21st. Finally, Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Seven equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.